Physician profile
David E Kim
NPI 1861541633
$6,593.88
in general payments reported to CMS, 2019-2025
28 companies · $677 in 2025
The $677 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $773 · 2021: $1,261 · 2022: $919 · 2023: $1,399 · 2024: $1,012 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,087.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,533.58 | 2020-2025 | Tremfya |
| Amgen INC. | $1,083.26 | 2019-2024 | Otezla, Enbrel |
| Glaxosmithkline, LLC. | $861.47 | 2019-2025 | Benlysta, Shingrix, Arexvy |
| Abbvie INC. | $647.25 | 2019-2025 | |
| Lilly USA, LLC | $470.25 | 2023-2025 | Taltz, Kisunla |
| Astrazeneca Pharmaceuticals Lp | $332.55 | 2020-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.68 | 2020-2025 | Ofev |
| Janssen Pharmaceuticals, INC | $226.07 | 2019-2023 | Xarelto |
| Fresenius Kabi USA, LLC | $205.10 | 2023-2025 | Idacio |
| Genzyme Corporation | $144.92 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $116.95 | 2020-2023 | Verquvo, Steglatro |
| Salvin Dental Specialties, INC. | $90.21 | 2020 | |
| Pfizer INC. | $86.61 | 2019-2024 | |
| Daiichi Sankyo INC. | $60.58 | 2021-2022 | |
| Exact Sciences Corporation | $58.59 | 2024-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $56.08 | 2019 | |
| Ethicon US, LLC | $46.00 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $35.80 | 2024 | Quviviq |
| Kiniksa Pharmaceuticals International, Plc | $30.61 | 2024 | Arcalyst |
| Sanofi Pasteur INC. | $30.19 | 2019 | |
| Zyla Life Sciences, INC. | $27.92 | 2019 | |
| Eisai INC. | $24.96 | 2021 | |
| Edwards Lifesciences Corporation | $24.47 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sumitomo Pharma America, INC. | $22.35 | 2024 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $19.69 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $19.42 | 2020 | |
| Alvogen INC | $18.55 | 2023 | Teriparatide |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.